Cyclo Therapeutics, Inc. Poster Presentation of Clinical Trial Data on Niemann-Pick Type C Disease at the 16th Annual WORLDSymposium Now Available

Data show that Trappsol® Cyclo™, the Company's proprietary hydroxypropyl beta cyclodextrin drug, reduces levels of trapped cholesterol in liver tissue of Niemann-Pick Disease Type C Patients

GAINESVILLE, FL – (Businesswire) – February 5, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer's Disease, today announced the online availability of its poster presentation at the WORLDSymposium ("We're Organizing Research on Lysosomal Diseases") to be held in Orlando, Florida, between February 10-13, 2020. The poster presentation (available HERE) is entitled, "Trappsol® Cyclo™ hydroxypropyl beta cyclodextrin administered intravenously in patients with Niemann-Pick Disease Type C reduces cholesterol in liver tissue." The presentation includes data from the Company's ongoing Phase I clinical trial in the United States to evaluate Trappsol® Cyclo™ administered intravenously in NPC in subjects 18 years and older (see ClinicalTrials.gov NCT02939547 for study parameters). The presentation shows that Trappsol® Cyclo™, when provided intravenously at levels as low as 1500 mg/kg, reduces trapped cholesterol in cells of NPC patients.

Cyclo Therapeutics, Inc. Chairman and CEO N. Scott Fine said, "These preliminary data further support the company moving forward as quickly as possible to get the drug to market authorization and begin helping patients."

Niemann-Pick Disease Type C is a rare and often fatal genetic disease affecting 1 in 100,000 live births globally. NPC affects every cell in the body due to the defect in the NPC protein which is responsible for cholesterol processing in the cell. The defect leads to cholesterol accumulation in every cell in the body, causing symptoms in the brain, liver, spleen, lung and other organs. There are no approved drug therapies for NPC in the United States, and only one, Miglustat/Zavesca, in Europe.

The Company's presentation was announced in press on December 16, 2019. Co-authors on the presentation are: Caroline Hastings MD and Benny Liu MD, Co-Principal Investigators of the clinical site based at UCSF Children's Hospital Oakland; Bryan Hurst MPhil, Cyclo Therapeutics partner at Boyd Consultants, UK, and Sharon Hrynkow PhD, the Company's Chief Scientific Officer and Senior Vice President for Medical Affairs.

Cyclo Therapeutics' presentation time is as follows:

Date: Wednesday, February 12, 2020

Time: 4:30 pm to 6:30 pm/Latebreaking Poster Session; Poster LB-18

Place: Hyatt Regency, Orlando, Florida

About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071), and in an Expanded Access program for late-onset Alzheimer's Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.cyclotherapeutics.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Investor/Media Contact:
RedChip Companies, Inc.
Victor Roberts
407-571-0909
victor@redchip.com